# A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

> **NCT06384352** · PHASE1 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 155 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** YL211

## Key facts

- **NCT ID:** NCT06384352
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-04-07
- **Final completion:** 2029-04-07
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06384352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06384352, "A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT06384352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*